![]() New-onset post-transplant diabetes and therapy in long-term survivors after allogeneic hematopoietic stem cell transplantation. Cell Metab 2023 35:414–28.e3.ĭalla Via V, Halter JP, Gerull S, Arranto C, Tichelli A, Heim D, et al. ![]() The global burden of metabolic disease: data from 2000 to 2019. Geographic distribution of metabolic syndrome and its components in the general adult population: a meta-analysis of global data from 28 million individuals. Noubiap JJ, Nansseu JR, Lontchi-Yimagou E, Nkeck JR, Nyaga UF, Ngouo AT, et al. Sherling DH, Perumareddi P, Hennekens CH. Metabolic syndrome prevalence by race/ethnicity and sex in the United States, National Health and Nutrition Examination Survey, 1988-2012. Prevalence of metabolic syndrome in the United States National Health and Nutrition Examination Survey (nhanes) 2011–2018. Liang XP, Or CY, Tsoi MF, Cheung CL, Cheung BMY, Pharmacology DOC, et al. Trends in the prevalence of metabolic syndrome in the United States, 2011-2016. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). 2005 366:1059–62.Įxpert Panel on Detection E, Treatment of High Blood Cholesterol in A. The metabolic syndrome-a new worldwide definition. Given the high prevalence of MetS in this cohort, clinicians should screen for its presence before it develops into comorbidities that complicate the course of cGVHD treatment.Īlberti KG, Zimmet P, Shaw J, Group IDFETFC. ![]() Additionally, there was no difference in cGVHD severity between the two groups. Patients with MetS compared to patients without MetS had no statistical differences in survival or NRM (5-year OS: 64% vs. Higher circulating erythrocyte sedimentation rate, C-reactive protein, and creatinine concentrations, along with lower estimated glomerular filtration rate, were associated with MetS ( P < 0.001 P < 0.004 P = 0.02 P = 0.002 respectively). Patients with higher body mass index and lower performance status scores were more likely to have MetS ( P < 0.0001 P = 0.026 respectively). A majority (54.1%, 124/229) of the cohort met the diagnostic criteria for MetS. Adult patients ( n = 229) with cGVHD enrolled in the cross-sectional NIH cGVHD Natural History Study (NCT00092235) were evaluated for MetS at enrollment and for variables associated with MetS. Patients with chronic graft-versus-host disease (cGVHD) are at heightened risk for components of metabolic syndrome (MetS), yet the prevalence and impact of MetS in the cGVHD patient population remain unknown.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |